Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
OPPORTUNITIES FOR TRAINEES TO PROMOTE DIVERSITY March 23, 2010 NSF Minority Faculty Development Workshop Alexis Bakos, PhD, MPH, RN,C Chief, Diversity Training Branch Center to Reduce Cancer Health Disparities, NCI Continuing Umbrella of Research Experiences HS Undergrad Predoctoral Postdoctoral Junior Investigator NRSA Fellowships: F31 and T32 S Diversity Supplements Supplements to the CURE: Cancer Center Grant: P30 Career Development R 03 SPORE: P50 Translational Cancer Center: P30 MD/POR R25T: Prevention and Control Clinical Oncology Training Grants: K12 Career Awards K01 K08 K23 Transition Career: K22 R 21 R 0 1 Supplement Eligibility Eligible Individuals Ethnic and/or racial minorities Socio-economically disadvantaged groups First generation college graduates Individuals with disabilities Must be US Citizen or permanent resident Eligible Grants ■ NCI grants Receipt of Supplement Applications by the NCI ■ Application Receipt: Two Cycles ■ October 1 through December 1 ■ March 1 through May 1 ■ Notice of Award: Office of Grants Administration Research Supplements to Promote Diversity in Health Related Research ■ Available for every career level e.g. High School through Junior faculty ■ Provides up to five years of support ■ * For T32, R25T, and K12 the supplement is awarded after slots are filled http://grants.nih.gov/grants/guide/pa-files/PA-08-190-html Supplements to Promote Reentry into Biomedical and Behavioral Research Careers Available for individuals who want to reestablish active research careers Provides up to 3 years of support Period of career interruption is 1 to 8 years Candidate must have a doctoral degree Support for salary, fringe benefits, supplies and travel http://grants.nih.gov/grants/guide/pa-files/PA-08-191.html Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research Mechanism: R21 (PAR-09-162) Purpose: To increase the diversity of the research workforce by supporting investigators from diverse populations in the area of basic cancer research. Direct Cost: $275,000 for 2 years Receipt Dates: Nov 23rd and June 23rd Exploratory/Developmental Grants Program for Basic Cancer Research in Cancer Health Disparities Mechanism: R21 (PAR-09-160) Purpose: To promote basic cancer research expertise in cancer health disparities Direct Cost: $275,000 for 2 yrs Receipt Date: Nov 23rd and June 23rd Basic Cancer Research in Cancer Health Disparities Mechanism: U01 (PAR-09-161) Cooperative agreement FOA to conduct basic research into the causes and treatment of cancer health disparities New methodologies Secondary data analyses Innovative mechanistic studies $250,000/yr for up to 5 yrs Receipt Date: Nov 23rd and June 23rd Office of Technology & Industrial Relations (OTIR) Innovative Technology Development for Cancer Research Mechanism R21 (RFA-CA-10-005) Feasibility studies on early stage development (i.e., at their conceptual stage where feasibility has not been established) of cancer-relevant technologies in the area of CA biology, prevention, diagnosis, treatment, epidemiology & cancer health disparities Up to $500,000 over 3 yr period Receipt Date: May 27 and Sept. 30, 2010 Office of Technology & Industrial Relations (OTIR) Application & Early Stage Development of Emerging Technology in Cancer Research Mechanism: R21 (RFA-CA-10-003) Feasibility studies on emerging cancer-relevant technologies (i.e., has passed the initial development stage but hasn’t been evaluated within the context of its intended use) in the area of CA biology, prevention, diagnosis, treatment, epidemiology & cancer health disparities Up to $275,000 direct costs over 2 yrs Receipt Date: May 27 and Sept. 30, 2010 Office of Technology & Industrial Relations (OTIR) Innovative & Early-Stage Development of Emerging Technologies in Biospecimen Science Mechanism R21 (RFA-CA-10-001) Early stage studies that develop technologies capable of interrogating &/or maximizing the quality & utility of biospecimens Up to $275,000 direct costs over 2 yrs Receipt Date: May 27 and Sept. 30, 2010 ■ Creates a pipeline of diverse cancer investigators ■ Investigators become mentors Example: Manuel Penichet, UCLA Recipient of: *Diversity Supplement *K award *R01s Manuel Penichet, M.D., Ph.D. Dr. Penichet and trainees DTB Contacts • For Supplements • Peter Ogunbiyi: [email protected] For R21 & U01 Funding Opportunities Anil Wali: [email protected] For OTIR Funding Opportunities LeeAnn Bailey: [email protected]